Vivo Opportunity, LLC purchased $10K of INM (indirect holdings)
Vivo Opportunity, LLC purchased 6,551 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.55 ($1.54–$1.55) across 6 trades over 2026-06-30 to 2026-07-02.
How this was made
The 30-second read
Why it matters
The disclosed open-market buying increases the owner’s indirect holdings to 73,135 shares, but the transaction value (~$10.1k) is unlikely to be material to valuation by itself.
Market read
Use as a sentiment/positioning datapoint for INM; it does not introduce new clinical, regulatory, or financial guidance.
What to watch
No 10b5-1 plan is cited, but the filing does not explain intent; traders should watch for follow-on Form 4s or other company-specific catalysts.
Background
The filing is an SEC Form 4 insider transaction for InMed Pharmaceuticals Inc. (INM) by Vivo Opportunity, LLC, identified as a 10% owner.
Ticker impact
Vivo Opportunity, LLC (10% owner) bought 6,551 INM shares in open-market trades at ~$1.54–$1.55 from 2026-06-30 to 2026-07-02.
Near-term: modest support to sentiment; likely limited price impact unless followed by additional disclosures or catalysts.
Form 4 is a primary-source insider transaction and is directionally supportive, but the disclosed size (~$10.1k) is small and lacks accompanying operational/regulatory/clinical news.
Market effects
No sector read-across; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
The purchase may be routine portfolio management rather than a conviction signal, especially given the small dollar value.
Key entities
- issuerInMed Pharmaceuticals Inc.
Subject of the Form 4; insider transaction disclosed for INM shares.
- insiderVivo Opportunity, LLC
10% owner who executed open-market purchases of INM shares (indirect holdings).
